The company's BAMS technology combines immuno-enrichment of protein targets with MALDI to enable rapid, multiplexed analysis of proteins and proteoforms.
Among firms presenting on the first day, 10x Genomics revealed it is developing a new high-throughput Chromium instrument, and Guardant plans to launch a comprehensive tissue sequencing assay.
The PCR-based panel is designed to simultaneously detect SARS-CoV-2, influenza A and B, and respiratory syncytial virus, with results in less than two hours.
The company said that it plans to use funds from its recent $18 million Series B round to drive instrument sales and develop AI tools for data analysis.
Canopy offers products and services for gene editing, gene expression analysis and regulation, and bioprocessing, as well as a multi-omic immune profiling platform.
The pair are working on reagents and mass spec approaches to improve isolation and analysis of crosslinked peptides for protein interaction and structural studies.
The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.
